LaNova Australia

LaNova Medicines is a clinical-stage biopharmaceutical company headquartered in Shanghai, specializing in the discovery and development of innovative biologics for oncology. The company focuses on three core technology pillars: a proprietary antibody-drug conjugate (ADC) platform, a next-generation antibody platform, and an immune-oncology platform. Its lead programs include LM-302, a Claudin 18.2-targeting ADC licensed to Bristol Myers Squibb, and LM-305, a GPRC5D-targeting ADC licensed to AstraZeneca. LaNova utilizes its Australian subsidiary, LaNova Medicines (Australia) Pty Ltd, to conduct early-stage clinical trials, benefiting from the region's efficient regulatory framework and R&D tax incentives. The company's pipeline is strategically designed to address unmet needs in solid tumors and hematological malignancies through high-affinity antibodies and optimized linker-payload technologies. With a strong focus on global partnerships and internal innovation, LaNova aims to deliver transformative therapies to cancer patients worldwide.